ROCHESTER, N.Y. -- Logical Images, developer of software that helps clinicians make faster and more accurate diagnoses of bioterrorism and other visually diagnosable conditions, announced that its flagship VisualDx® software system has been chosen by the Delaware Division of Public Health for installation in hospitals statewide. The system is being funded through grants from the National Bioterrorism Hospital Preparedness Program, administered by the federal Health Resources & Services Administration (HRSA).
Were pleased that Delaware chose VisualDx as a way to increase bioterrorism preparedness, said Michael OConnor, president of Logical Images. VisualDx will be installed in every acute-care hospital emergency department in the state, he added.
VisualDx is an interactive software system that allows clinicians to input specific information based on their examination of a patient. The system then searches its database of more than 10,000 images of 600 diseases and comes up with high-quality photos and descriptions of possible conditions that fit the information the doctor has input, enabling a rapid and more accurate diagnosis and prompt treatment. Because of its detailed information on anthrax, smallpox and other agents that might be intentionally released by terrorists, bioterrorism preparedness experts describe VisualDx as a valuable tool in the war on terrorism.
VisualDx was designed as a dual-purpose system, so in addition to its terrorism-related capabilities, it is used on a daily basis in hospitals, clinics and public-health settings to quickly and accurately identify visually diagnosable conditions such as infectious diseases, sexual transmitted diseases, skin conditions, oral lesions, drug eruptions, and the like, said Art Papier, MD, Logical Images chief scientific officer. Particularly in areas with limited access to dermatologists or infectious-disease specialists, VisualDx helps emergency physicians and primary care doctors by giving them visual as well as textual information so they can make an accurate diagnosis and start the right treatment quickly.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.